{"id":34092,"date":"2025-05-26T11:47:17","date_gmt":"2025-05-26T03:47:17","guid":{"rendered":"https:\/\/flcube.com\/?p=34092"},"modified":"2025-05-26T11:47:18","modified_gmt":"2025-05-26T03:47:18","slug":"medtronics-prevail-dcb-gains-ce-mark-for-expanded-coronary-disease-indications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34092","title":{"rendered":"Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications"},"content":{"rendered":"\n

US-Irish firm Medtronic (NYSE: MDT<\/a>) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (drug-coated balloon, DCB) has received CE Mark certification in the European Union. This certification expands the device’s indications for treating various coronary artery disease (CAD) conditions, making it the only DCB approved for treating multivessel disease, acute coronary syndrome (ACS), and diabetic patients.<\/p>\n\n\n\n

Broadest CE-Approved Indications<\/strong>
The Prevail DCB now holds the broadest CE-approved indications among DCBs, including bifurcation lesions. This approval underscores Medtronic’s commitment to advancing cardiovascular treatments and providing healthcare professionals with versatile tools to address complex coronary conditions.<\/p>\n\n\n\n

Clinical Trial Data<\/strong>
At the Cardiovascular Research Technologies (CRT) conference, clinical trial data revealed the Prevail DCB’s effectiveness, showing low event rates over two years. The data highlighted a 6.1% rate of new-onset myocardial infarction (MI), a 7.4% target lesion revascularization (TLR) rate, and a 0.8% incidence of definitive target lesion thrombosis. In hybrid percutaneous coronary intervention (PCI) procedures, which combine DCB and drug-eluting stents (DES), the Prevail DCB demonstrated numerically lower rates of new-onset MI compared to other DCBs.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA)…<\/p>\n","protected":false},"author":1,"featured_media":34094,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[69,233,1031,15],"class_list":["post-34092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-cvd","tag-medtronic","tag-nyse-mdt","tag-product-approvals"],"yoast_head":"\nMedtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (drug-coated balloon, DCB) has received CE Mark certification in the European Union. This certification expands the device's indications for treating various coronary artery disease (CAD) conditions, making it the only DCB approved for treating multivessel disease, acute coronary syndrome (ACS), and diabetic patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34092\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications\" \/>\n<meta property=\"og:description\" content=\"US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (drug-coated balloon, DCB) has received CE Mark certification in the European Union. This certification expands the device's indications for treating various coronary artery disease (CAD) conditions, making it the only DCB approved for treating multivessel disease, acute coronary syndrome (ACS), and diabetic patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34092\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-26T03:47:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-26T03:47:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2601.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications\",\"datePublished\":\"2025-05-26T03:47:17+00:00\",\"dateModified\":\"2025-05-26T03:47:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092\"},\"wordCount\":194,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2601.webp\",\"keywords\":[\"CVD\",\"Medtronic\",\"NYSE: MDT\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34092#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34092\",\"name\":\"Medtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2601.webp\",\"datePublished\":\"2025-05-26T03:47:17+00:00\",\"dateModified\":\"2025-05-26T03:47:18+00:00\",\"description\":\"US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (drug-coated balloon, DCB) has received CE Mark certification in the European Union. This certification expands the device's indications for treating various coronary artery disease (CAD) conditions, making it the only DCB approved for treating multivessel disease, acute coronary syndrome (ACS), and diabetic patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34092\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2601.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2601.webp\",\"width\":1080,\"height\":608,\"caption\":\"Medtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34092#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Medtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications - Insight, China's Pharmaceutical Industry","description":"US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (drug-coated balloon, DCB) has received CE Mark certification in the European Union. This certification expands the device's indications for treating various coronary artery disease (CAD) conditions, making it the only DCB approved for treating multivessel disease, acute coronary syndrome (ACS), and diabetic patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34092","og_locale":"en_US","og_type":"article","og_title":"Medtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications","og_description":"US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (drug-coated balloon, DCB) has received CE Mark certification in the European Union. This certification expands the device's indications for treating various coronary artery disease (CAD) conditions, making it the only DCB approved for treating multivessel disease, acute coronary syndrome (ACS), and diabetic patients.","og_url":"https:\/\/flcube.com\/?p=34092","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-26T03:47:17+00:00","article_modified_time":"2025-05-26T03:47:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2601.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34092#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34092"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications","datePublished":"2025-05-26T03:47:17+00:00","dateModified":"2025-05-26T03:47:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34092"},"wordCount":194,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34092#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2601.webp","keywords":["CVD","Medtronic","NYSE: MDT","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34092#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34092","url":"https:\/\/flcube.com\/?p=34092","name":"Medtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34092#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34092#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2601.webp","datePublished":"2025-05-26T03:47:17+00:00","dateModified":"2025-05-26T03:47:18+00:00","description":"US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (drug-coated balloon, DCB) has received CE Mark certification in the European Union. This certification expands the device's indications for treating various coronary artery disease (CAD) conditions, making it the only DCB approved for treating multivessel disease, acute coronary syndrome (ACS), and diabetic patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34092#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34092"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34092#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2601.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2601.webp","width":1080,"height":608,"caption":"Medtronic's Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34092#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2601.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34092"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34092\/revisions"}],"predecessor-version":[{"id":34095,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34092\/revisions\/34095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34094"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}